BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program

SAN FRANCISCO – May 29, 2020 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, QED’s oral FGFR1-3 inhibitor, in both urothelial carcinoma and cholangiocarcinoma (CCA). Title: Infigratinib (BGJ398) in advanced/unresectable or […]

BridgeBio Pharma’s Phoenix Tissue Repair Provides Updates to its Recessive Dystrophic Epidermolysis Bullosa (RDEB) Program and Announces New Leadership Appointments

BOSTON — May 13, 2020 – Phoenix Tissue Repair, Inc. (PTR), an affiliate company of BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced updates to its ongoing Phase 1/2 study of PTR-01 (BridgeBio designation BBP-589), an intravenously-administered recombinant collagen 7 protein replacement therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB). Cohorts 1 – 3 have completed […]

BridgeBio Pharma, Inc. Reports First Quarter 2020 Financial Results and Business Update

–Ended quarter with $928 million in cash, cash equivalents and marketable securities SAN FRANCISCO, May 13, 2020 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), today reported its financial results for the first quarter ended March 31, 2020 and provided an update on the company’s operations. The company is working with its committed partners to minimize disruption from […]

BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia

Data Accepted to ENDO 2020 SAN FRANCISCO – May 11, 2020 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that in vitro and in vivo data from two studies support QED’s plans to evaluate a low dose of infigratinib as a treatment option for children with achondroplasia, the most common cause of […]

BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference

PALO ALTO, Calif., May 6, 2020 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced today that it will present at the Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 11 AM (ET). The presentation will be webcast live and can be accessed at www.bridgebio.com on the For Investors page under News & Events. The webcast will […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., May 5, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on May 1, 2020, the compensation committee of BridgeBio’s board of directors granted five employees options to purchase an aggregate of 39,600 shares of the Company’s common stock with a […]